An extract of Artemisia dracunculus L. enhances insulin receptor signaling and modulates gene expression in skeletal muscle in KK-Ay mice

Journal of Nutritional Biochemistry

Volumn 22, Issue 1, 2011, Pages 71-78

  Wang, Zhong Q ^a   Ribnicky, David ^b   Zhang, Xian H ^a   Zuberi, Aamir ^a   Raskin, Ilya ^b   Yu, Yongmei ^a   Cefalu, William T ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Botanicals; Insulin signaling; Muscle; Nutrition

Indexed keywords

ARTEMISIA DRACUNCULUS EXTRACT; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT EXTRACT; PMI 5011; PROTEASOME; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTEMISIA; ARTEMISIA DRACUNCULUS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FOOD INTAKE; GENE EXPRESSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VASTUS LATERALIS MUSCLE;

ANIMALS; ARTEMISIA; DIETARY SUPPLEMENTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MICE; MICE, MUTANT STRAINS; MUSCLE, SKELETAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHYTOTHERAPY; PLANT EXTRACTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RANDOM ALLOCATION; RECEPTOR, INSULIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; UBIQUITINATED PROTEINS;

ANIMALIA; ARTEMISIA DRACUNCULUS; MUS;

EID: 78651378631     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.11.015     Document Type: Article

References (31)

1. Haffner S.M. Impaired glucose tolerance, insulin resistance and cardiovascular disease. Diabet Med 1997, 14(3):S12-S18.
2. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006, 38(1):64-80.
3. Riddle M.C. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins and combinations. Endocrinol Metab Clin North Am 2005, 34:77-98.
4. Stafylas P.C., Sarafidis P.A., Lasaridis A.N. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009, 131(3):298-304.
5. Schmidt B., Ribnicky D.M., Poulev A., Logendra S., Cefalu W.T., Raskin I. A natural history of botanical therapeutics. Metabolism 2008, 57(7 Suppl 1):S3-S9.
6. Cusi K., DeFronzo R.A. Metformin: a review of its metabolic effects. Diabetes Rev 1998, 6:89-131.
7. Cefalu W.T., Brantley P.J. Botanicals and cardiometabolic risk: positioning science to address the hype. Metabolism 2008, 57(7 suppl 1):S1-S2.
8. Swanston-Flatt S.K., Flatt P.R., Day C., Bailey C.J. Traditional dietary adjuncts for the treatment of diabetes mellitus. Proc Nutr Soc 1991, 50:641-651.
9. Ribnicky D.M., Poulev A., Watford M., Cefalu W.T., Raskin I. Antihyperglycemic activity of TARRALIN™, an ethanolic extract of Artemisia dracunculus L. Phytomedicine 2006, 13:550-557.
10. Zuberi A.R. Strategies for assessment of botanical action on metabolic syndrome in the mouse and evidence for a genotype-specific effect of Russian tarragon in the regulation of insulin sensitivity. Metabolism 2008, 57(7 Suppl 1):S10-S15.
11. Wang Z.Q., Ribnicky D.M., Zhang X.H., Raskin I., Yu Y., Cefalu W.T. Bioactives of Artemisia dracunculus L enhance cellular signaling in primary human skeletal muscle culture. Metabolism 2008, 57(7):S58-S64.
12. Logendra S., Ribnicky D.M., Yang H., Poulev A., Ma J., Kennelly E.J., Raskin I. Bioassay-guided isolation of aldose reductase inhibitors from Artemisia dracunculus. Phytochemistry 2006, 67:1539-1546.
13. Ribnicky D.M., Kuhn P., Poulev A., Logendra S., Zuberi A., Cefalu W.T., Raskin I. Improved absorption and bioactivity of active compounds from an anti-diabetic extract of Artemisia dracunculus L. Int J Pharm 2009, 370(1-2):87-92.
14. Govorko D., Logendra S., Wang Y., Esposito D., Komarnytsky S., Ribnicky D., et al. Polyphenolic compounds from Artemisia dracunculus L. inhibit PEPCK gene expression and gluconeogenesis in an H4IIE hepatoma cell line. Am J Physiol Endocrinol Metab 2007, 293(6):E1503-E1510.
15. Reddi A.S., Camerini-Davalos R.A. Hereditary diabetes in the KK mouse: an overview. Adv Exp Med Biol 1988, 246:7-15.
16. Sugiura M., Hirano K.A. A new colorimetric method for determination of serum glucose. Clin Chim Acta 1977, 75:387-391.
17. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
18. Wang Z.Q., Floyd Z.E., Qin J., Liu X., Yu Y., Zhang X.H., et al. Modulation of skeletal muscle insulin signaling with chronic caloric restriction in cynomolgus monkeys. Diabetes 2009, 58(7):1488-1498.
19. Wang Z.Q., Zhang X.H., Russell J.C., Hulver M., Cefalu W.T. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 2006, 136(2):415-420.
20. Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on bias and variance. Bioinformatics 2003, 19(2):185-193.
21. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998, 95:14863-14868.
22. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998, 17:7151-7160.
23. Kornitzer D., Ciechanover A. Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol 2001, 182:1-11.
24. Voges D., Zwickl P., Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999, 68:1015-1068.
25. Dube N., Tremblay M.L. Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer. Biochim Biophys Acta 2005, 1754(1-2):108-117.
26. Goldstein B.J. Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance. Curr Drug Targets Immune Endocr Metabol Disord 2001, 1(3):265-275.
27. Ahmad F., Azevedo J.L., Cortright R., Dohm G.L., Goldstein B.J. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 1997, 100(2):449-458.
28. Worm D., Vinten J., Staehr P., Henriksen J.E., Handberg A., Beck-Nielson H. Altered basal and insulin-stimulate phosphotyrosine phosphatase (PTPase) activity in skeletal muscle from NIDDM patients compared with control subjects. Diabetologia 1996, 39:1208-1214.
29. Kusari J., Kenner K.A., Suh K.I., Hill D.E., Henry R.R. Skeletal muscle protein tyrosine phosphatase activity and tyrosine phosphatase 1B protein content are associated with insulin action and resistance. J Clin Invest 1994, 93(3):1156-1162.
30. Goldstein B.J. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocrinol Metab 2002, 87(6):2474-2480.
31. Kheterpal I., Coleman L., Ku G., Wang Z.Q., Ribnicky D., Cefalu W.T. Regulation of insulin action by an extract of Artemisia dracunculus L. in primary human skeletal muscle culture - a proteomics approach. Phytother Res 2010, [Epub ahead of print].